DK2909196T3 - Bicykliske heterocykliske forbindelser og anvendelser deraf ved terapi - Google Patents

Bicykliske heterocykliske forbindelser og anvendelser deraf ved terapi Download PDF

Info

Publication number
DK2909196T3
DK2909196T3 DK13780387.0T DK13780387T DK2909196T3 DK 2909196 T3 DK2909196 T3 DK 2909196T3 DK 13780387 T DK13780387 T DK 13780387T DK 2909196 T3 DK2909196 T3 DK 2909196T3
Authority
DK
Denmark
Prior art keywords
therapy
heterocyclic compounds
bicyclic heterocyclic
bicyclic
compounds
Prior art date
Application number
DK13780387.0T
Other languages
Danish (da)
English (en)
Inventor
Gianni Chessari
Christopher Norbert Johnson
Lee William Page
Ildiko Maria Buck
James Edward Harvey Day
Steven Howard
Gordon Saxty
Christopher William Murray
Anna Hopkins
Original Assignee
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astex Therapeutics Ltd filed Critical Astex Therapeutics Ltd
Application granted granted Critical
Publication of DK2909196T3 publication Critical patent/DK2909196T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
DK13780387.0T 2012-10-19 2013-10-18 Bicykliske heterocykliske forbindelser og anvendelser deraf ved terapi DK2909196T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261716086P 2012-10-19 2012-10-19
GBGB1218862.9A GB201218862D0 (en) 2012-10-19 2012-10-19 Bicyclic heterocycle compounds and their uses in therapy
PCT/GB2013/052720 WO2014060767A1 (en) 2012-10-19 2013-10-18 Bicyclic heterocycle compounds and their uses in therapy

Publications (1)

Publication Number Publication Date
DK2909196T3 true DK2909196T3 (da) 2021-03-01

Family

ID=47359189

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13780387.0T DK2909196T3 (da) 2012-10-19 2013-10-18 Bicykliske heterocykliske forbindelser og anvendelser deraf ved terapi

Country Status (10)

Country Link
US (1) US9617283B2 (OSRAM)
EP (1) EP2909196B1 (OSRAM)
JP (1) JP6381534B2 (OSRAM)
KR (1) KR102299834B1 (OSRAM)
CN (1) CN104870441B (OSRAM)
CA (1) CA2888107C (OSRAM)
DK (1) DK2909196T3 (OSRAM)
ES (1) ES2847897T3 (OSRAM)
GB (1) GB201218862D0 (OSRAM)
WO (1) WO2014060767A1 (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
GB201106814D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compounds
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
ES2883289T3 (es) * 2013-12-20 2021-12-07 Astex Therapeutics Ltd Compuestos heterocíclicos bicíclicos y sus usos en terapia
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
US10781205B2 (en) 2016-04-20 2020-09-22 Glaxosmithkline Intellectual Property Development Limited Conjugates comprising RIPK2 inhibitors
EP3455221B1 (en) * 2016-05-09 2020-03-11 H. Hoffnabb-La Roche Ag Dimeric compounds
CN118436801A (zh) 2016-05-20 2024-08-06 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
GB201610147D0 (en) 2016-06-10 2016-07-27 Glaxosmithkline Ip Dev Ltd Novel compounds
CN106265764B (zh) 2016-08-18 2018-03-16 广州威溶特医药科技有限公司 Iap抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用
CN109535070B (zh) * 2018-12-27 2022-03-29 青岛清原化合物有限公司 吡啶氧基羧酸酯衍生物及其制备方法、除草组合物和应用
BR112021012415B1 (pt) 2018-12-27 2024-02-15 Qingdao Kingagroot Chemical Compound Co., Ltd Derivado de piridiloxicarboxilato, composição herbicida compreendendo o mesmo, método para preparar o mesmo, bem como método e uso do dito derivado para controlar erva daninha
EP3947368B1 (en) 2019-04-04 2025-09-03 Dana-Farber Cancer Institute, Inc. Bifunctional compounds comprising a cdk2/5 ligand, a linker and a e3 ubiquitin ligase binding degron for the treatment of cancer
CA3148504A1 (en) 2019-08-08 2021-02-11 Institute For Cancer Research D/B/A/ The Research Institute Of Fox Chase Cancer Center Combination therapy for treatment of cancer
CN110483509B (zh) * 2019-09-04 2020-08-25 温州大学 一种合成含氮杂环衍生物的方法
CN110627785B (zh) * 2019-09-19 2021-06-25 温州大学 一种1,5-四氢萘啶衍生物的制备方法
CN120247907A (zh) * 2020-05-04 2025-07-04 大塚制药株式会社 Iap拮抗剂化合物和中间体及其合成方法
EP4161937A4 (en) * 2020-06-04 2024-06-12 BeiGene, Ltd. PYRIDO[2, 3-B] [1, 4] OXAZINES OR TETRAHYDROPYRIDO [2, 3-B] [1, 4] OXAZEPINES USED AS IAP ANTAGONISTS
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
CN116731016A (zh) * 2022-03-11 2023-09-12 苏州亚盛药业有限公司 作为iap拮抗剂的三环杂环化合物
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080330A (en) 1975-06-23 1978-03-21 Delmar Chemicals Limited Phenylindolines and process for their production
DE3822792C2 (de) 1987-07-11 1997-11-27 Sandoz Ag Neue Verwendung von 5HT¶3¶-Antagonisten
TW218875B (OSRAM) 1992-03-09 1994-01-11 Takeda Pharm Industry Co Ltd
NZ321575A (en) 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
EP0778277B1 (en) 1995-12-08 2003-06-25 Pfizer Inc. Substituted heterocyclic derivatives as CRF antagonists
DK0892780T3 (da) 1996-02-22 2003-03-03 Bristol Myers Squibb Pharma Co m-Amidinophenylanaloger som faktor Xa-inhibitorer
EP0944388A4 (en) 1996-04-03 2001-08-16 Merck & Co Inc INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
AU719102B2 (en) 1996-06-28 2000-05-04 Merck & Co., Inc. Fibrinogen receptor antagonist prodrugs
US5977134A (en) 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2001524116A (ja) 1997-04-18 2001-11-27 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 5ht1a、5ht1bおよび5ht1d受容体アンタゴニスト活性を合わせ持つインドール誘導体
US6084098A (en) 1999-02-26 2000-07-04 Neurogen Corporation Benzylpiperazinyl and piperidinyl ethanone derivatives: dopamine receptor subtype specific ligands
WO1999050247A1 (en) 1998-03-31 1999-10-07 Acadia Pharmaceuticals, Inc. Compounds with activity on muscarinic receptors
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
US6608084B1 (en) 1998-08-26 2003-08-19 Aventis Pharma Ltd. Aza-bicycles which modulate the inhibition of cell adhesion
GB9905010D0 (en) 1999-03-04 1999-04-28 Merck Sharp & Dohme Therapeutic agents
AU3555200A (en) 1999-03-17 2000-10-04 F. Hoffmann-La Roche Ag Oxazolone derivatives and their use as alpha-1 adrenoreceptor modulators
GB9929552D0 (en) 1999-12-14 2000-02-09 Proteus Molecular Design Compounds
WO2001012600A1 (en) 1999-08-12 2001-02-22 Cor Therapeutics, Inc. INHIBITORS OF FACTOR Xa
ATE399753T1 (de) 1999-09-04 2008-07-15 Astrazeneca Ab Amide als pyruvatdehydrogenaseinhibitoren
GB0031088D0 (en) 2000-12-20 2001-01-31 Smithkline Beecham Plc Medicaments
CA2433090A1 (en) 2000-12-27 2002-07-04 Kyowa Hakko Kogyo Co., Ltd. Dipeptidyl peptidase iv inhibitor
AU2002303264A1 (en) 2001-04-09 2002-10-21 Bristol-Myers Squibb Company Fused heterocyclic inhibitors of factor xa
JP2004534017A (ja) 2001-04-27 2004-11-11 バーテックス ファーマシューティカルズ インコーポレイテッド Baceのインヒビター
AU2003235097A1 (en) 2002-04-24 2003-11-10 Takeda Pharmaceutical Company Limited Use of compounds having ccr antagonism
BRPI0408136A (pt) 2003-03-07 2006-03-01 Astellas Pharma Inc derivados heterocìclicos contendo nitrogênio tendo estirila 2,6-dissubstituìda
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
US7514438B2 (en) 2003-08-13 2009-04-07 Amgen, Inc. Melanin concentrating hormone receptor antagonist
TW200524887A (en) 2003-10-27 2005-08-01 Lundbeck & Co As H N-thiazol-2-yl-benzamide derivatives
US7674787B2 (en) 2004-07-09 2010-03-09 The Regents Of The University Of Michigan Conformationally constrained Smac mimetics and the uses thereof
WO2006032987A1 (en) 2004-09-23 2006-03-30 Pfizer Products Inc. Indoline compounds and their use in the treatment of arteriosclerosis
ATE477254T1 (de) 2004-12-20 2010-08-15 Genentech Inc Pyrrolidine als inhibitoren von iap
CN101128425B (zh) * 2005-02-25 2012-12-26 泰特拉洛吉克药业公司 Iap二聚体抑制剂
WO2007073405A1 (en) 2005-12-21 2007-06-28 Decode Genetics Ehf N-linked aryl heteroaryl inhibitors of lta4h for treating inflammation
FR2896504B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
GB0602335D0 (en) 2006-02-07 2006-03-15 Remynd Nv Thiadiazole Derivatives For The Treatment Of Neurodegenerative Diseases
WO2008014252A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Iap inhibitors
US8044209B2 (en) * 2006-10-12 2011-10-25 Novartis Ag Pyrrolydine derivatives as IAP inhibitors
PT2099769E (pt) * 2006-12-07 2012-08-31 Novartis Ag 6-oxo-1,6-di-hidropirimidin-2-ilos no tratamento de doenças proliferativas
CA2680312A1 (en) 2007-03-07 2008-09-12 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
WO2008116107A2 (en) 2007-03-21 2008-09-25 Takeda San Diego, Inc. Piperazine derivatives as glucokinase activators
KR20100119768A (ko) * 2008-01-24 2010-11-10 테트랄로직 파마슈티칼스 코포레이션 아이에이피 억제제
WO2009147476A1 (en) 2008-06-02 2009-12-10 Matrix Laboratories Ltd. Novel pde inhibitors, pharmaceutical compositions containing them and processes for their preparation
US9174969B2 (en) 2008-07-21 2015-11-03 University Of South Florida Indoline scaffold SHP-2 inhibitors and cancer treatment method
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
WO2010121212A2 (en) 2009-04-17 2010-10-21 H. Lee Moffit Cancer Center And Research Institute, Inc. Indoline scaffold shp-2 inhibitors and method of treating cancer
MX2011011735A (es) 2009-05-04 2011-11-29 Plexxikon Inc Compuestos y metodos para la inhibicion de renina, e indicaciones para ello.
WO2010138666A1 (en) 2009-05-28 2010-12-02 Tetralogic Pharmaceuticals Corp. Iap inhibitors
GB201106814D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compounds
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
US9499479B2 (en) 2011-10-03 2016-11-22 The Trustees Of Columbia University In The City Of New York Molecules that selectively inhibit histone deacetylase 6 relative to histone deacetylase 1
PL2800738T3 (pl) 2012-01-06 2020-10-19 Novartis Ag Związki heterocykliczne i sposoby ich stosowania
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
ES2883289T3 (es) 2013-12-20 2021-12-07 Astex Therapeutics Ltd Compuestos heterocíclicos bicíclicos y sus usos en terapia
JP6510539B2 (ja) 2014-01-09 2019-05-08 ザ ジェイ. デヴィッド グラッドストーン インスティテューツ, ア テスタメンタリー トラスト エスタブリッシュド アンダー ザ ウィル オブ ジェイ. デヴィッド グラッドストーン 置換ベンゾオキサジン及び関連化合物

Also Published As

Publication number Publication date
CN104870441A (zh) 2015-08-26
EP2909196A1 (en) 2015-08-26
CN104870441B (zh) 2017-09-29
CA2888107C (en) 2023-10-31
WO2014060767A1 (en) 2014-04-24
JP6381534B2 (ja) 2018-08-29
CA2888107A1 (en) 2014-04-24
KR20150072435A (ko) 2015-06-29
US20150259359A1 (en) 2015-09-17
ES2847897T3 (es) 2021-08-04
US9617283B2 (en) 2017-04-11
KR102299834B1 (ko) 2021-09-07
GB201218862D0 (en) 2012-12-05
JP2016500684A (ja) 2016-01-14
EP2909196B1 (en) 2020-12-02

Similar Documents

Publication Publication Date Title
DK2909196T3 (da) Bicykliske heterocykliske forbindelser og anvendelser deraf ved terapi
DK2909198T3 (da) Bicykliske heterocykliske forbindelser og anvendelser deraf ved terapi
DK2699562T3 (da) Bicykliske heterocykliske forbindelser og anvendelser deraf ved terapi
DK2909197T3 (da) Bicykliske heterocykliske forbindelser og anvendelser deraf ved terapi
DK3083616T3 (da) Bicykliske heterocykliske forbindelser og disses anvendelser i terapi
DK3608325T3 (da) Polycykliske-carbamoylpyridonforbindelser og deres farmaceutiske anvendelse
BR112014031436A2 (pt) comparar e substituir entrada de tabela dat
IL235590A0 (en) Phototherapy devices and methods
ZA201405253B (en) Heterocyclic compounds and methods for their use
EP2867209A4 (en) COMPOUNDS AND THEIR THERAPEUTIC USES
ZA201405255B (en) Heterocyclic compounds and methods for their use
ZA201405257B (en) Heterocyclic compounds and methods for their use
DK2917181T3 (da) Heteroarylderivater og anvendelser deraf
AP3611A (en) Heterocyclic compounds and their uses
DK2943460T3 (da) 6-chlor-3-(phenyl-d5)-inden-1-on og anvendelse deraf
DK3211410T3 (da) Elektrode og anvendelse deraf
IL237150A0 (en) Treatment regimens
GB201322755D0 (en) Bicyclic heterocycle compounds and their uses in therapy
BR302012006074S1 (pt) Configuracao em conjunto de talheres
BR302012006072S1 (pt) Configuracao em conjunto de talheres